Circulating tumour cell isolation, analysis and clinical application
Authors (first, second and last of 4)
Collection
Circulating Tumor DNA
Circulating tumor DNA is a promising liquid biopsy marker for cancer diagnosis, treatment selection and clinical follow-up of cancer patients. This series focuses on ongoing developments in circulating tumor DNA, as well as the techniques and clinical research methods, which ultimately integrates liquid biopsy into the clinical workflow.
All article types accepted.
Editors
-
Dr. Cun Wang
Dr. Cun Wang obtained his Ph.D. degree in 2012 in Biochemistry and Molecular Biology from Fudan University, China. In 2012, he joined the laboratory of Prof. Wenxin Qin at Shanghai Cancer Institute, China. From 2016 to 2019, he joined the group of Prof. René Bernards at the Netherlands Cancer Institute in Amsterdam to investigate drug resistance in liver cancer. In 2019, he was appointed as professor at Shanghai Cancer Institute. His laboratory focuses on identifying powerful therapeutic strategies for liver cancer through functional genetic screens.
-
Dr. Xiaohang Qiao
Dr. Xiaohang Qiao obtained her Ph.D. degree in 2010 on molecular immunology from the Institute of Biophysics, Chinese Academy of Sciences. From 2010 to 2016, she joined the group of Prof. Jacques Neefjes at the Netherlands Cancer Institute (Nederlands Kanker Instituut, NKI) to investigate the molecular mechanisms of anti-cancer drugs. After that, she joined the laboratory of Prof. Lotje Zuur at NKI to explore the novel therapeutic targets and neoadjuvant immunotherapy for head and neck cancer (HNC). In 2017, she was appointed as Associate Staff Scientist in the department of Tumor Biology and Immunology at NKI.
